Log in to search using one of your social media accounts:

Well: Ask Well: Why Is Arthritis More Common in Women Than Men?
More women than men get arthritis over all, but there are many types of arthritis, and some types are more common in men. (Source: NYT Health)
Source: NYT Health - April 12, 2016 Category: Consumer Health News Authors: RONI CARYN RABIN Tags: Ask Well Arthritis Rheumatoid Arthritis Autoimmune Diseases Lupus Erythematosus Women and Girls Live Featured Aging Osteoarthritis Source Type: news

Well: Ask Well: Why Is Arthritis More Common in Women Than Men?
More women than men get arthritis over all, but there are many types of arthritis, and some types are more common in men. (Source: NYT)
Source: NYT - April 12, 2016 Category: Nutrition Authors: RONI CARYN RABIN Tags: Ask Well Arthritis Rheumatoid Arthritis Autoimmune Diseases Lupus Erythematosus Women and Girls Live Featured Aging Osteoarthritis Source Type: news

Rheumatology community responds to FDA approval of Inflectra (Infliximab-dyyb), a Biosimilar to Remicade
The ACR has issued an official statement regarding the FDA's approval of Inflectra (infliximab-dyyb), a biosimilar to Remicade. Inflectra is the first biosimilar to receive approval in the U.S. for the treatment of rheumatic diseases, including rheumatoid arthritis and psoriatic arthritis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 7, 2016 Category: Science Source Type: news

Inflectra Approved as 'Biosimilar' to Remicade
For adults with Crohn's, rheumatoid arthritis or psoriasis (Source: U.S. News - Health)
Source: U.S. News - Health - April 6, 2016 Category: Consumer Health News Source Type: news

Inflectra Approved as 'Biosimilar' to Remicade
WEDNESDAY, April 6, 2016 -- The U.S. Food and Drug Administration has approved its second-ever "biosimilar" drug, Inflectra, for adults with Crohn's disease, rheumatoid arthritis or chronic plaque psoriasis, among other prescribed uses. In a media... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 6, 2016 Category: Journals (General) Source Type: news

FDA Approves Remicade Biosimilar (Inflectra)FDA Approves Remicade Biosimilar (Inflectra)
The second biosimilar approved in the United States, this version of infliximab is indicated for Crohn's disease, rheumatoid arthritis, and almost all other conditions listed for the original. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 5, 2016 Category: Consumer Health News Tags: Internal Medicine News Alert Source Type: news

New rheumatoid arthritis drug 'can succeed where others fail'
A new therapy for rheumatoid arthritis has shown potential to effectively treat patients who have failed to respond to other types of therapy.The new drug, baricitinib, is currently still in the clinical testing phase, but if approved it could represent a promising new therapeutic option for people with refractory rheumatoid arthritis, who currently have few options available to them.A new treatment approach Baricitinib was tested in a phase III clinical trial, led by Stanford University in the US and the Medical University of Vienna in Austria, to determine the drug's effectiveness in patients who had not benefite...
Source: Arthritis Research UK - April 5, 2016 Category: Rheumatology Source Type: news

FDA Approves Rheumatoid Arthritis Knockoff
U.S. regulators cleared for sale a knockoff version of Johnson & Johnson’s Remicade anti-inflammatory drug, the second entry in a fledgling U.S. market for lower-cost copies of pricey biotechnology drugs. (Source: WSJ.com: Health)
Source: WSJ.com: Health - April 5, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news

FDA approves biosimilar to J&J's Remicade for multiple diseases
(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson & Johnson's drug Remicade, to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine. (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Why I Eat Red Meat
So many of us have omitted or cut down on our consumption of red meat due to negative reports in the press. However, I believe that unprocessed, grass-fed beef has its place in a healthy diet. Besides the fact that nothing is better than a juicy hamburger on the grill in the summer, the high levels of nutrients it provides can make it a healthy choice. Here are some of the stand-out nutrients you might be missing: Iron Iron is an essential nutrient involved in many different metabolic functions. It is especially important in early childhood cognitive development, energy metabolism and the immune system. One of its most cr...
Source: Healthy Living - The Huffington Post - April 5, 2016 Category: Consumer Health News Source Type: news

Study: Smoking Hikes Chances of Early Death for Rheumatoid Arthritis Patients
Title: Study: Smoking Hikes Chances of Early Death for Rheumatoid Arthritis PatientsCategory: Health NewsCreated: 4/4/2016 12:00:00 AMLast Editorial Review: 4/5/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - April 5, 2016 Category: Rheumatology Source Type: news

Study: Smoking hikes chances of early death for rheumatoid arthritis patients
HealthDay News Smoking increases the chances of early death in people with rheumatoid arthritis, but quitting smoking significantly reduces that risk, a new study suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 5, 2016 Category: Consumer Health News Source Type: news

Arthritis patients 'can fend off early death by quitting smoking'
Rheumatoid arthritis patients can potentially increase their life expectancy simply by quitting smoking, according to a new Arthritis Research UK-backed study.The University of Manchester study has offered evidence that smoking can be associated with earlier deaths in people with rheumatoid arthritis, but also that this effect can be reversed by kicking the habit.Stephen Simpson, director of research and programmes at Arthritis Research UK, said: "Rheumatoid arthritis is a debilitating and painful condition affecting over 400,000 people in the UK. It can begin at any age and is unpredictable - one day you can feel fin...
Source: Arthritis Research UK - April 4, 2016 Category: Rheumatology Source Type: news

New study shows benefits of rapid-access rheumatology clinics
People with rheumatological conditions could be diagnosed more promptly and effectively by introducing new rapid-access rheumatology services, according to a new study.Conducted by the University of Vienna in Austria, the research indicates that such clinics, offered via doctors' surgeries, could help drive improvements in the standard of care offered to these patients.The benefits of rapid-access services Currently, waiting times for initial appointments are a major obstacle to the timely provision of rheumatology care. As such, this study aimed to see whether a cooperative of surgery-based rheumatologists working...
Source: Arthritis Research UK - April 4, 2016 Category: Rheumatology Source Type: news

Navidea to seek rheumatoid arthritis indication for Lymphoseek
Navidea (NYSE:NAVB) said today it is beginning the clinical trial development process as it seeks an indication for its Lymphoseek injection for treating rheumatoid arthritis and other disease states. The decision came after a recent meeting with the FDA, the Dublin, Ohio-based company said. “Our efforts to continue to unlock the significant value of the Manocept platform are well underway as we seek to expand Lymphoseek’s label so it can be used as an immunodiagnostic for additional diseases. This collaborative meeting with FDA has enabled us to continue to advance the regulatory process and begin to...
Source: Mass Device - April 4, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Imaging Oncology Regulatory/Compliance Navidea Biopharmaceuticals Source Type: news

Study: Smoking Hikes Chances of Early Death for Rheumatoid Arthritis Patients
But risk declines after quitting, researchers find (Source: U.S. News - Health)
Source: U.S. News - Health - April 4, 2016 Category: Consumer Health News Source Type: news

Study: Smoking Hikes Chances of Early Death for Rheumatoid Arthritis Patients
But risk declines after quitting, researchers find Source: HealthDay Related MedlinePlus Pages: Rheumatoid Arthritis, Smoking (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 4, 2016 Category: Consumer Health News Source Type: news

Study: Smoking Hikes Chances of Early Death for Rheumatoid Arthritis Patients
MONDAY, April 4, 2016 -- Smoking increases the chances of early death in people with rheumatoid arthritis, but quitting smoking significantly reduces that risk, a new study suggests. "This research provides important evidence that the risk of early... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 4, 2016 Category: Journals (General) Source Type: news

Suicide: Unseen Public Health Crisis
Longtime political consultant Ron Oliver divides his life into before Aug. 31, 2013, and after. That’s the morning he discovered that his wife of 31 years, Floy, had hanged herself in the garage of their North Little Rock home. “Since this happened to me, I wonder now when I read obituaries how many of them might have been suicides,” Oliver said last week. “Before, I never thought about it.” Some of them undoubtedly are. Suicide is the 10th most common cause of death in the United States, and Arkansas’ rate of suicide, 17.4 per 100,000 residents in 2014, is 30 percent higher than the nat...
Source: Arkansas Business - Health Care - April 4, 2016 Category: American Health Source Type: news

New study highlights long-term tolerability of anti-TNF therapies
This study provides reassuring evidence that anti-TNF therapies are effective in some patients over long periods of time; however, it also highlights the importance of selecting the right drug for each patient, as a large number of people with arthritis have to switch between therapies during a course of treatment."We are funding research which aims to help doctors predict which patients will respond best to which therapies, helping to speed up the time it takes to get the right treatment to the right patient." (Source: Arthritis Research UK)
Source: Arthritis Research UK - April 3, 2016 Category: Rheumatology Source Type: news

Samsung Nears European Approval for Near-Replica Version of Arthritis Drug
Samsung Group’s drug-development arm said it is on track to win European regulatory approval for a near-replica version of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade. (Source: WSJ.com: Health)
Source: WSJ.com: Health - April 1, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news

Experimental Drug for Rheumatoid Arthritis Shows Promise
Title: Experimental Drug for Rheumatoid Arthritis Shows PromiseCategory: Health NewsCreated: 3/31/2016 12:00:00 AMLast Editorial Review: 4/1/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - April 1, 2016 Category: Rheumatology Source Type: news

Baricitinib Offers Promise of Remission in Refractory RA Baricitinib Offers Promise of Remission in Refractory RA
The oral Janus kinase 1 and 2 inhibitor baricitinib significantly increased ACR20 response rates and improved physical function in patients with rheumatoid arthritis for whom other therapies had failed. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 1, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Experimental Drug for Rheumatoid Arthritis Shows Promise
Baricitinib helped patients who failed other treatments, researchers find (Source: U.S. News - Health)
Source: U.S. News - Health - March 31, 2016 Category: Consumer Health News Source Type: news

Experimental Drug for Rheumatoid Arthritis Shows Promise
Baricitinib helped patients who failed other treatments, researchers find Source: HealthDay Related MedlinePlus Page: Rheumatoid Arthritis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 31, 2016 Category: Consumer Health News Source Type: news

New drug effective for refractory rheumatoid arthritis
Stephen FellerSTANFORD, Calif., March 31 (UPI) -- In a clinical trial, the drug baricitinib was shown to be effective in rheumatoid arthritis patients with lessening or no response to other treatments. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 31, 2016 Category: Consumer Health News Source Type: news

New drug for the treatment of rheumatoid arthritis shows promising success
In a clinical phase-3-study, an international research cooperation has achieved significant success with the drug Baricitinib for the treatment of rheumatoid arthritis. The test persons exhibited significantly less symptoms of the disorder. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 31, 2016 Category: Science Source Type: news

Experimental Drug for Rheumatoid Arthritis Shows Promise
THURSDAY, March 31, 2016 -- An experimental drug to treat rheumatoid arthritis showed promise in a new six-month trial. Baricitinib substantially reduced symptoms and improved daily physical functioning among people who failed other treatments for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 31, 2016 Category: Journals (General) Source Type: news

Arthritis Research UK Fellow wins prestigious Garrod prize
Congratulations to Dr Helen McGettrick, a career development fellowship holder from the University of Birmingham, who has been awarded the prestigious Garrod prize. Awarded annually by the British Society of Rheumatology, this prize is open to scientists with a non-clinical background who are working in rheumatology or a related discipline. The award is named after Sir Alfred Baring Garrod, who was responsible for recognising the difference between osteoarthritis and rheumatoid arthritis and for initiating the thread test for uric acid in the blood. Helen’s research focuses on exploring the role played by synovial f...
Source: Arthritis Research UK - March 30, 2016 Category: Rheumatology Source Type: news

New Imaging Modality to Detect Inflammation in RA and OANew Imaging Modality to Detect Inflammation in RA and OA
Do we need new imaging modalities for the assessment of inflammation in rheumatoid arthritis and osteoarthritis? Annals of the Rheumatic Diseases (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - March 30, 2016 Category: Radiology Tags: Rheumatology Journal Article Source Type: news

We should be ashamed if we don’t pass Tobacco 21 laws
Follow me at @drClaire In the United States, the national drinking age is 21. States can make it younger, but if they do they lose federal highway funding. The idea is that youth less than 21 are more likely to run into trouble if they drink, and that having them wait until they are older is better. You can argue about whether this actually works, but the idea is a good one. And yet when it comes to tobacco, as far as the federal government is concerned, you just have to be 18. Which, for anyone who knows anything about what happens when youth smoke, makes no sense at all. It was really Mothers Against Drunk Driving (MADD)...
Source: New Harvard Health Information - March 29, 2016 Category: Consumer Health News Authors: Claire McCarthy, MD Tags: Addiction Behavioral Health Children's Health Parenting Prevention Smoking cessation tobacco 21 laws Source Type: news

RasGRP1 and RasGRP3 in Rheumatoid ArthritisRasGRP1 and RasGRP3 in Rheumatoid Arthritis
What roles do RasGRP1 and RasGRP3 play in rheumatoid arthritis pathophysiology? Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Benefits of anti-TNF treatment for psoriatic arthritis highlighted by study
This study was significant as it utilised data from patients in a real-world setting, rather than controlled test conditions. This provides doctors with a clearer view of how drugs work in routine clinical practice.A total of 420 biologic-naive patients with psoriatic arthritis, who were beginning treatment with the anti-TNF therapies adalimumab, etanercept or infliximab, were enrolled in the trial, with their progress followed over four years.Attention was paid to drug survival rates - the number of people remaining on treatment after a given period - as well as how many of the patients continued to rely on glucocorticoid...
Source: Arthritis Research UK - March 28, 2016 Category: Rheumatology Source Type: news

An Open Letter to the Boston Globe About Lyme Disease
Today, the Boston Globe editorial board spoke out against a bill "that would require insurers in Massachusetts to cover Lyme disease treatments for as long as a doctor says they're needed." The Globe writes: Lawmakers may have good intentions, but they don't possess the expertise to decide whether it's beneficial, cost-efficient, or safe, to keep using strong medicines to treat a condition the medical establishment doubts is real. Such questions should be resolved by a consensus of doctors and researchers -- and buttressed by convincing clinical date [sic] -- not determined by legislative mandate. Who among the B...
Source: Healthy Living - The Huffington Post - March 28, 2016 Category: Consumer Health News Source Type: news

Smoking and RA: A Deadly Combination (CME/CE)
(MedPage Today) -- Medium-term mortality doubled in smokers with rheumatoid arthritis (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 27, 2016 Category: Geriatrics Source Type: news

Antibiotics Side Effects on the Mitochondria
Science is just beginning to understand how important your mitochondria are to warding off the diseases of aging. And, as usual, mainstream medicine is lagging way behind. Along with your telomeres, the cellular time keepers at the ends of your chromosomes, your mitochondria are another key component of the anti-aging equation. You see, these tiny organelles in your cells are the power plants that turn fuel into energy for your body. Healthy mitochondria keep you young and energetic.  Research shows that damaged mitochondria can lead to: Schizophrenia and bipolar disorder; Alzheimer’s and Parkinson’s d...
Source: Al Sears, MD Natural Remedies - March 25, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Natural Cures Source Type: news

Prooxidants may fix metabolic defect in arthritis-driving T cells
Researchers have uncovered a metabolic defect that spurs T cells to go rogue in rheumatoid arthritis patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 23, 2016 Category: Science Source Type: news

Claims that man flu 'really exists' are unsupported
Conclusion This small laboratory study points to specific biological mechanisms that might explain why women are more likely to suffer autoimmune disorders, such as SLE, than men. It found the second silenced copy of the X chromosome in women can be partially reactivated and express immune-related genes, instead of staying completely silent. Though this is a plausible reason for the overactive immune system found in SLE, it does not explain why men can also have the condition. Also, only SLE was investigated in this study and with blood samples from just five children with the condition. It is not clear at this stage how...
Source: NHS News Feed - March 23, 2016 Category: Consumer Health News Tags: Lifestyle/exercise Medical practice Source Type: news

Rheumatoid Arthritis Progression Rate Has Halved Since 1990 Rheumatoid Arthritis Progression Rate Has Halved Since 1990
The rate of radiographic progression in RA has decreased during the last 20 years, in tandem with changes in RA treatment practices. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 22, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Antisclerostin osteoporosis drugs might worsen or unmask rheumatoid arthritis
Antisclerostin monoclonal antibodies have shown their ability to increase bone density in phase II and III trials of men and women with osteoporosis but could potentially have the opposite effect in... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - March 21, 2016 Category: Endocrinology Source Type: news

Pfizer's Xeljanz meets goals in ulcerative colitis trials
(Reuters) - Pfizer Inc said on Friday its Xeljanz rheumatoid arthritis drug succeeded in meeting primary and secondary goals of a pair of late stage clinical trials in ulcerative colitis, results that could help pave the way for an additional approval for the oral medicine. (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Mucosal Immune Tolerance in Rheumatoid ArthritisMucosal Immune Tolerance in Rheumatoid Arthritis
Does rheumatoid arthritis originate as mucosal inflammation in an extra-articular location? Read why many believe this is the case. Rheumatology (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - March 16, 2016 Category: Orthopaedics Tags: Rheumatology Journal Article Source Type: news

The Healing Power Of Poop May Surprise You
SAN DIEGO -- Last week at the inaugural Near Future Summit, a leadership conference of forward-thinking professionals, tech entrepreneur Peter Diamandis asked members of the audience to raise their hands if they'd been born vaginally. He then asked them to keep their hands raised if they had also been breastfed and if, in more recent years, they'd avoided antibiotics, Z-Paks and major surgery. In the end, just a few dozen people in the audience of 250 or so still had their hands up.  This wasn't just an exercise in TMI: Diamandis was hoping to assess the microbiome status of his listeners. All of the aforeme...
Source: Science - The Huffington Post - March 15, 2016 Category: Science Source Type: news

Conversations That Cut the Medical Bill (Jim Karrh On Marketing)
Considering all of the technical advances and new complexities in marketing today (such as social, digital and automation), I see the major opportunity for most organizations to be a decidedly analog one. Customer conversations — those interactions in real time, generally face to face — are ripe for improving engagement, service levels, loyalty and growth. A remarkable new study of the conversations between doctors and patients also shows that more proactive face-to-face interactions can even lower costs. The study comes from Duke University’s Fuqua School of Business, the Duke University School of Medici...
Source: Arkansas Business - Health Care - March 14, 2016 Category: American Health Source Type: news

Drug Combo Shuts Down Stem Cells, Tumor Growth in Lung Cancer
JACKSONVILLE, Fla. — Researchers on Mayo Clinic’s Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent. The combination therapy worked in a laboratory study to stop lung adenocarcinoma associated with mutation of the KRAS gene. The [...] (Source: Mayo Clinic Florida News)
Source: Mayo Clinic Florida News - March 14, 2016 Category: Hospital Management Source Type: news

Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
TARRYTOWN, N.Y. and PARIS, March 11, 2016 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was sup... BiopharmaceuticalsRegeneron Pharmaceuticals, Sanofi, sarilumab, rheumatoid arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 11, 2016 Category: Pharmaceuticals Source Type: news

Xeljanz XR (tofacitinib citrate) Modified Release Tablets For the Treatment of Rheumatoid Arthritis
Xeljanz XR (tofacitinib citrate) is an 11mg once-daily oral JAK inhibitor developed by Pfizer for the treatment of moderate to severe Rheumatoid Arthritis (RA). (Source: Drug Development Technology)
Source: Drug Development Technology - March 11, 2016 Category: Pharmaceuticals Source Type: news

People with arthritis given equal say in research funding decisions
A pioneering pilot approach to patient involvement means Arthritis Research UK is blazing a trail among UK medical research charities to make sure people with arthritis are at the very heart of decision-making on research funding. Chris Macdonald, our research involvement manager, explains: "Each year we fund around £25m worth of research into the cause, treatment and cure of arthritis so people can live pain-free lives. What better way to make sure this research is of high quality and relevant to the lives of people with arthritis than to make sure their voice is heard loud and clear when we make funding decis...
Source: Arthritis Research UK - March 10, 2016 Category: Rheumatology Source Type: news